Spyre Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Spyre Therapeutics has a total shareholder equity of $374.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $436.1M and $61.7M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$426.00m |
| Aandelen | US$374.39m |
| Totaal verplichtingen | US$61.68m |
| Totaal activa | US$436.07m |
Recente financiële gezondheidsupdates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Recent updates
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Oct 01Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17Analyse van de financiële positie
Kortlopende schulden: SYRE's short term assets ($435.7M) exceed its short term liabilities ($22.1M).
Langlopende schulden: SYRE's short term assets ($435.7M) exceed its long term liabilities ($39.6M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: SYRE is debt free.
Schuld verminderen: SYRE has not had any debt for past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: SYRE has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: SYRE has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 14.1% each year.